Breaking Down Barriers: Why Early Commercialization Planning is Key to a Successful Market Entry Strategy

Moderator: Samantha Gleason

Speakers: Kim Riggs & Nancy Young

Regulatory approval is not the finish line. It is the beginning of the commercialization journey.

Discover why early commercialization planning matters, and how emerging biopharma companies can make smarter development and commercialization decisions to support successful market entry and long-term product success. When commercialization planning starts too late, the consequences can surface quickly: evidence gaps, misaligned comparators, limited reimbursement potential, and reduced strategic flexibility.

Watch the recording to recap the discussion with our experts on why commercialization planning should begin in phase 2 and phase 3, not at launch.

Key highlights

• How to align evidence planning with both regulatory and payer expectations.
• Why patient population and label strategy can directly influence access and reimbursement.
• How early comparator strategy and stakeholder engagement can reduce downstream risk.
• Which operational and go-to-market decisions can affect uptake, access, and long-term commercial performance.